Examining PCSK9 Inhibitor Use in the Post-MI Patient: Evidence and Examples
Examining PCSK9 Inhibitor Use in the Post-MI Patient: Evidence and Examples is organized by Medscape, LLC.
CME / ABIM MOC / CE Released: 1/7/2021
Valid for credit through: 1/7/2022
Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The goal of this activity is to improve understanding of lipid-lowering guidelines and the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients at very high risk for cardiovascular (CV) events, including a potential role in post-myocardial infarction (MI) patients.
Upon completion of this activity, participants will:
• Have increased knowledge regarding the
○ Guideline recommendations for lipid lowering and CV risk reduction in post-MI patients
○ Safety and efficacy of PCSK9 inhibitors in post-MI patients
• Have greater competence related to
○ Individualization of lipid-lowering therapy in patients with acute coronary syndrome (ACS)
- CME : 1
- MOC : 1
Toll free Number
Browse CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Immunology and Microbiology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine